Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 6/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.37 |
| ▸ | PARP15 | Q460N3 | 4/20 | 0.37 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.35 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24933356 | 0.86 | PARP10 (0.52) | PARP10PARP15PARP2FFAR4CHEK2 | |
| SCHEMBL24933633 | 0.85 | PARP10 (0.53) | PARP10PARP15PARP2FFAR4CHEK2 | |
| SCHEMBL24932946 | 0.84 | XDH (0.42) | IRAK4PARP10PARP15HSD17B1HSD17B2 | |
| SCHEMBL24933017 | 0.84 | PRKAB2 (0.42) | PARP10PARP15HSD17B1HSD17B2PARP2 | |
| SCHEMBL24933789 | 0.82 | CHEK2 (0.42) | PARP10PARP15PARP2CHEK2 | |
| SCHEMBL24933589 | 0.82 | XDH (0.49) | IRAK4PARP10PARP15HSD17B1HSD17B2 | |
| SCHEMBL24933255 | 0.81 | CHEK2 (0.47) | CHEK2 | |
| SCHEMBL24933840 | 0.81 | PRKAB2 (0.46) | PARP10PARP15HSD17B1HSD17B2FFAR4 | |
| SCHEMBL29203336 | 0.81 | CHEK2 (0.52) | IRAK4PARP10PARP15PARP2CHEK2 | |
| SCHEMBL24933256 | 0.81 | PDK2 (0.43) | HSD17B1HSD17B2FFAR4CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | claimed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | claimed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | claimed |
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |